AEGiS-AP: FDA Wants Women in Drug Studies

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

FDA Wants Women in Drug Studies

The Associated Press; 50 Rockefeller Plaza, New York, NY 10020 - Tuesday, September 23, 1997; 3:58 p.m. EDT

WASHINGTON (AP) -- The Food and Drug Administration moved Tuesday to force drug companies to stop excluding young women from studies of promising new medicines merely for fear they'll get pregnant during the research.

For years, doctors as well as the government considered it wise to keep women of childbearing age out of medical studies because some drugs can harm a developing fetus.

Women's advocates attacked that policy as paternalistic, saying it kept women with life-threatening diseases away from studies of promising therapies even though women today can use highly effective contraceptives. Such studies are often how dying patients get the quickest access to new drugs.

AIDS activists especially urged a change, saying that HIV-infected women were being unfairly denied access to AIDS drug studies.

The FDA told drug companies in 1993 to include women in all phases of a drug's testing. But when the agency examined 4,000 clinical studies performed in the last three years, it found about 25 percent still excluded women solely because they could have gotten pregnant, said Deputy Commissioner Mary Pendergast.

So Tuesday, the FDA proposed a regulation that would force companies to change by letting the FDA halt or prevent clinical trials of drugs for serious or life-threatening illnesses that exclude women for reproductive reasons.

Even if a drug is suspected of causing birth defects, "they have to give the woman the right to make the decision," Pendergast said. The proposal "sends a strong message to the industry that we really do want them to open the doors of trials to women."

The drug industry did not immediately comment.

The gender rules would not apply to clinical trials designed to study only healthy volunteers, not patients, or those studying male-only conditions like prostate cancer.

The public can comment on the proposal for 90 days; the FDA then will decide whether to make it final.

Copyright 1997/The Associated Press. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, The Associated Press, 50 Rockefeller Plaza, New York, NY 10020.
970923
AP970913

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .